Saratov JOURNAL of Medical and Scientific Research

Influence of valsartan on clinical and instrumental parameters in patients suffering from chronic heart failure with mid-range ejection fraction

Year: 2021, volume 17 Issue: №1 Pages: 19-22
Heading: Cardiology Article type: Original article
Authors: Glebova Т.А., Galin P.Yu.
Organization: City Clinical Hospital n. a. N.I. Pirogov, Orenburg State Medical University

Purpose: to establish the effectiveness of valsartan in patients with chronic heart failure with mid-range ejection fraction from the standpoint of influencing the clinic, the parameters of central hemodynamics and the level of natriuretic peptide. Material and Methods. Our study included 45 patients with CHF with mid-range ejection fraction, with NYHA (New York Heart Association) functional class II (FC). All patients underwent a comprehensive clinical and standard echocardiographic examination. Valsartan was administered in titrated dosages up to the maximum tolerated ortarget daily dose in accordance with the recommendations. The observation period was one year. Results. During the observation period, 89% of patients switched from FC II to FC I of CHF (p<0.001), the left ventricular (LV) ejection fraction increased from 46 (44-47) % to 55 (53-60) % (p<0,05), the level of natriuretic peptide decreased from 455 (397-513) pg/ml to 210 (146-343) pg/ml (p<0.05). Conclusion. The use of valsartan in patients with CHF with mid-range ejection fraction improves the clinical condition and parameters of central hemodynamic during a year of observation.

1. Garganeeva AA, Baujer VA, Borel' KN. The pandemic of the XXI century: chronic heart failure-the burden of modern society. Epidemiological aspects. Siberian Medical Journal 2014; 29 (3): 8-12.
2. Ponikowski Р, Voors AA, Anker SD, et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment af acute and chronic heart failure of the European Society of Cardioligy (ESC) Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J 2016; 37 (27): 2129-200.
3. Tsuji K, Sakata Y, Nochioca K, et al. Characterization of heart failure patients with mid-range left ventricular ejection fraction a report from the CHART-2 Study: Characterization of HFmrEF. European Journal of Heart Failure 2017; 19 (10): 1258-6.
4. Cohn JN, Tognoni G. A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. N Engl J Med 2001; (345): 1667-75.
5. Zadionchenko VS, Shehjan GG, Byl'eva AA, et al. Valsartan in the treatment of diseases of the circulatory system. Russian Medical Journal 2011; 19 (4): 236-42.
6. Shevchenko OP, Shevchenko АО. АСЕ inhibitors in patients with heart failure. Russian Journal of Cardiology 2008; 13 (5): 76-83.
7. Klingbeil AU, Schneider М, Martus Р, et al. A meta-analysis of the effects of treatment on left ventricular mass in essential hypertension. Am J Med 2003; 115 (1): 41 -6.
8. Lukowucz T, Fisher M, Hense H, et al. BNP as a marker of diastolic disfunction in general population: Importance of left ventricular hypertrophy. Eur J Heart Fail 2005; (7): 525-31.
9. Lubien E, DeMaria A, Krishnaswamy K. Utility of B-natriuretic peptide in diagnosing diastolic dysfunction. Circ 2002; (105): 595-601.
10. Baryshnikova GA. Comparative meta-analysis of the effectiveness of sartans in the treatment of arterial hypertension. Russian Medical Journal 2010; 18 (22): 1356-59.

2021_01_019-022.pdf304.61 KB

No votes yet